Coherus Oncology (CHRS) FCF Margin Growth (5y) (2019 - 2026)
Coherus Oncology (CHRS) FCF Margin Growth (5y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43,330.00 |
| Mar 31, 2026 | -47,171.00 |
| Dec 31, 2025 | -24,950.00 |
| Sep 30, 2025 | -44,032.00 |
| Jun 30, 2025 | 421,688.00 |
| Mar 31, 2025 | -41,203.00 |
| Dec 31, 2024 | 35,672.00 |
| Sep 30, 2024 | -107,394.00 |
| Jun 30, 2024 | 95,369.00 |
| Mar 31, 2024 | 626,616.00 |
| Jun 30, 2022 | 395,357.00 |
| Mar 31, 2022 | 4.65 Mn |
| Dec 31, 2021 | 1.10 Mn |
| Sep 30, 2021 | 5,435.00 |
| Jun 30, 2021 | 17,811.00 |
| Mar 31, 2021 | 63,635.00 |
| Dec 31, 2020 | -2,545.00 |
| Sep 30, 2020 | 87,164.00 |
| Jun 30, 2020 | 32,698.00 |
| Mar 31, 2020 | 60,172.00 |